B
Bo Ahrén
Researcher at Lund University
Publications - 803
Citations - 42013
Bo Ahrén is an academic researcher from Lund University. The author has contributed to research in topics: Insulin & Glucagon. The author has an hindex of 97, co-authored 794 publications receiving 39757 citations. Previous affiliations of Bo Ahrén include Malmö University & Umeå University.
Papers
More filters
Journal ArticleDOI
Interleukin-6-deficient mice develop mature-onset obesity.
Ville Wallenius,Kristina Wallenius,Bo Ahrén,Mats Rudling,Hans Carlsten,Suzanne L. Dickson,Claes Ohlsson,John-Olov Jansson +7 more
TL;DR: In this article, the authors investigated the impact of loss of IL-6 on body composition in mice lacking the gene encoding interleukin-6 (Il6-/- mice) and found that they developed mature-onset obesity that was partly reversed by IL-six replacement.
Journal ArticleDOI
Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.
TL;DR: GLIP has an antidiabetogenic effect, and it may therefore be useful in the treatment of patients with NIDDM, indicating that GLIP had an insulinotropic effect.
Journal ArticleDOI
The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes.
Maria Sörhede Winzell,Bo Ahrén +1 more
TL;DR: It is concluded that the high-fat diet-fed C57BL/6J mouse model is a robust model for IGT and early type 2 diabetes, which may be used for studies on pathophysiology and development of new treatment.
Journal ArticleDOI
Autonomic regulation of islet hormone secretion--implications for health and disease.
TL;DR: It is concluded that islet innervation, through the contribution of all branches of the autonomic nerves and several different neurotransmitters is of importance both for the physiology and pathophysiology of the islets.
Journal ArticleDOI
Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes
TL;DR: Improved metabolic control by DPP-4 inhibition in type 2 diabetes is seen in association with reduced glucagon levels and, despite the lower glycemia, unaltered insulin levels.